Ground substance

Hydrochloric Acid Market Size to Grow by USD 978.77 million, 5.72% YOY market growth in 2023-2024, Technavio

Retrieved on: 
Giovedì, Marzo 14, 2024
Carbon, Resin, Chlorine, PVC, Hydrochloric acid, BASF, Growth, Occidental Petroleum, Olin Corporation, Steel, Tessenderlo Group, COVID-19, Hydrogen chloride, Alkyl polyglycoside, APG, Food, Synthetic, AGC, Fructose, Merck Group, HFCS, Mining, Hazardous waste, Chemistry, Drink, Vinyl chloride, Optimism, Ground substance, USD, SGL Carbon, PCC, Palladium

The food segment, valued at USD 689.47 million in 2018, drives significant growth in the hydrochloric acid market.

Key Points: 
  • The food segment, valued at USD 689.47 million in 2018, drives significant growth in the hydrochloric acid market.
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global hydrochloric acid market.
  • Expansion of hydrochloric acid facilities, like SGL Carbon's unit delivery to Travancore-Cochin Chemicals Ltd., drives market growth, enabling companies to enhance their market presence and offer a wider product range, boosting the global hydrochloric acid market.
  • Substitutes like emerald-safe acid, phosphoric acid, sodium bisulfate, and trisodium phosphate pose challenges to hydrochloric acid market growth.

Can B Corp. Secures Ownership and Control of Two Cannabis Patents Valued at $122 Million and Potentially in Excess of $750 Million

Retrieved on: 
Lunedì, Marzo 11, 2024
OTCQB, Cancer, Anxiety, THCA, Shikimate pathway, Growth, CBN, Cannabinoid, European, Health, Ground substance, Chronic pain, Patent, Federal court, THC, PTSD, Cannabis, Sleep, IBS, Controlled Substances Act, Pharmaceutical industry

HICKSVILLE, NY, March 11, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Can B Corp., a Florida corporation (OTCQB: CANB) (“Can B”), a health and wellness company specializing in developing, producing and selling hemp-derived cannabinoid products, is pleased to announce that it has secured ownership and control of two cannabis patents that were valued at $122 million, applying a 90% discount and assuming a revenue stream through August 2034, and further based on only CBD claims and only in the U.S. It is believed that if the global THC and CBD markets were added to the valuation, then the value of the patents is potentially up to $750 million.

Key Points: 
  • It is believed that if the global THC and CBD markets were added to the valuation, then the value of the patents is potentially up to $750 million.
  • These patents were previously awarded to United Cannabis Corporation and recently assigned to Can B by a court procedure.
  • The patents were valued at $122 million in December 2020 by an independent third-party valuation team, which used a 90% discount rate due to the emerging nature of the industry.
  • We believe there is a strong opportunity to monetize these patents as they represent important innovations in this industry.

Verano Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Giovedì, Febbraio 29, 2024
News, Growth, Table, Sale, Commerce, Capital expenditure, Ground substance, GAAP, Webcast, Public expenditure, Legislation, Commerce Clause, Bank statement, Depreciation, Controlled Substances Act, Video game

CHICAGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced its financial results for the fourth quarter and full year ended December 31, 2023, which were prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”).

Key Points: 
  • Net loss for the fourth quarter 2023 was $(73) million, or (31)% of revenue, versus a loss of $(216) million in the fourth quarter 2022, and $(18) million for the third quarter 2023.
  • Net cash provided by operating activities for the fourth quarter 2023 was $32 million, up from $29 million for the fourth quarter 2022.
  • Capital expenditures for the fourth quarter 2023 were $10 million, up from $9 million for the fourth quarter 2022.
  • Free cash flow1 for the fourth quarter 2023 was $23 million, up from $20 million for the fourth quarter 2022.

BRIGHT GREEN CORPORATION GAINS MOMENTUM FOR THEIR “DRUGS MADE IN AMERICA” PLATFORM WITH APPROVAL FOR THE RESEARCH, PRODUCTION AND MANUFACTURING OF ALL SCHEDULE I AND SCHEDULE II PLANT-BASED DRUGS

Retrieved on: 
Giovedì, Febbraio 22, 2024
Psilocybin, Cocaine, Medicine, Research, API, Opium, Active ingredient, DEA, Federation, Ground substance, Policy, Uncertainty, Mescaline, Partnership, Drug

GRANTS, N.M., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) company announced today that final approval has been received from the New Mexico Board of Pharmacy and the DEA for unique licensing that allows Bright Green to register, license, and authorize Schedule I and Schedule II plant-based drugs and Active Pharmaceutical Ingredients (APIs) for research, production, and manufacturing purposes. Schedule I Substances include Psilocybin, psilocybin, mescaline, peyote, ibogaine Schedule II Substances: Opium, poppy straw, raw opium, opium extracts, powdered opium, granulated opium, tincture of opium, opium fluid extracts, opium straw concentrates, pending: erythroxylon coca (cocaine)

Key Points: 
  • Achieving this substantial approval allows Bright Green to bring their deep expertise to these issues to help propel our Drugs Made in America movement forward.
  • The research will be conducted the Company’s C2 team in Albuquerque, New Mexico, and the reshoring of production and manufacturing to the U.S. will take place at the company’s Grants, New Mexico facility.
  • Medical plants will be produced in climate-controlled glass greenhouses engineered to ensure quality and predictability, laying a roadmap for guaranteed supply contracts with both federal government entities and other pharmaceutical interests.
  • Bright Green expects to be the first company in almost 100 years to produce, manufacture and supply API for Schedule I and Schedule II controlled substances and to deliver on contracts of this type.

Plant Biostimulants Market Projected to Reach $6.6 Billion Globally by 2030, Driven by Technological Advancements and Sustainable Farming Practices - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Febbraio 19, 2024
Agriculture, Natural Resources, Growth, Ground substance, GDP, COVID-19, Gross domestic product, Amino acid, Renewable energy

The global Plant Biostimulants market, valued at US$2.7 Billion in 2022, is on a robust growth trajectory with expectations to reach a substantial US$6.6 Billion by the year 2030.

Key Points: 
  • The global Plant Biostimulants market, valued at US$2.7 Billion in 2022, is on a robust growth trajectory with expectations to reach a substantial US$6.6 Billion by the year 2030.
  • This growth represents a compound annual growth rate (CAGR) of 11.8% over the forecast period from 2022-2030.
  • The impressive expansion reflects a rising demand for sustainable agriculture solutions as well as proactive government policies endorsing environmentally friendly farming practices.
  • The United States Plant Biostimulants market is currently assessed at US$457.4 Million, establishing itself as a considerable player within the industry in 2022.

First-Chair Federal Prosecutor Andrea Surratt Joins Crowell & Moring

Retrieved on: 
Lunedì, Marzo 4, 2024
Virginia School for Girls, Joint Terrorism Task Force, Moses Austin, Bank, Narcotic, Fraud, Pharmacy, Offense, Government, Cryptocurrency, Bank Secrecy Act, Digital asset, Ground substance, University, Homicide, DOJ, Law, White collar, Surratt, Justice

DENVER, March 4, 2024 /PRNewswire/ -- Andrea Surratt, a former Assistant U.S. Attorney in both the Southern District of New York and the District of Colorado, has joined Crowell & Moring's Denver office in the White Collar and Regulatory Enforcement Group.

Key Points: 
  • A seasoned prosecutor, Surratt has served as first-chair for sophisticated investigations, trials, and appeals involving money laundering, fraud offenses, sanctions and export controls, gaming, cybercrime, cryptocurrency, and national security issues.
  • "It is a particular point of pride for me to watch Andrea rise through the ranks of two different U.S. Attorney's offices and then join our growing Denver office."
  • As chief of the narcotics unit in the SDNY, Surratt supervised 30 junior federal prosecutors and oversaw a wide range of complex cross-border money laundering and narcotics trafficking investigations.
  • "In leaving the government, I knew I wanted to find a collaborative team that values each individual's input and experience to achieve excellent results for clients, and Crowell is that place," Surratt said.

Canon recognized with highest A score for its climate change activities from CDP

Retrieved on: 
Giovedì, Febbraio 29, 2024
United Nations Global Compact, World Resources Institute, WRI, Steam, Canon Inc., WWF, Ground substance, Climate change, Biodiversity, CDP, Organization, CO2, A-list, Science Based Targets initiative, Electricity, Recycling, Science, GHG, Category, Environment, Renewable energy

The CDP evaluates major companies and local governments worldwide on their efforts to tackle environmental issues.

Key Points: 
  • The CDP evaluates major companies and local governments worldwide on their efforts to tackle environmental issues.
  • Evaluations are based on information disclosed in response to questions sent to the companies regarding such topics as climate change and water resource management.
  • This is Canon's third time earning a spot on the A List in the climate change category, having been included in the A List previously in 2016 and 2020.
  • Canon will continue working to make various technological advancements and improve managerial efficiency to help to reduce CO2 throughout society.

Healthcare False Claims Act Cases Account for Two-Thirds of Fraud Recoveries in Federal Fiscal Year 2023

Retrieved on: 
Mercoledì, Febbraio 28, 2024
Human services, Quackery, Pharmacy, Court, Accusative case, Federation, Government, HHS, SCOTUS, FCA, Health care, Ground substance, DOJ, Bass, False Claims Act, FY, Publication, Supreme court, Controlled Substances Act, Pharmaceutical industry

NASHVILLE, Tenn., Feb. 28, 2024 /PRNewswire-PRWeb/ -- The U.S. Department of Justice (DOJ) reported civil fraud recoveries of nearly $2.7 billion in fiscal year (FY) 2023, with two-thirds of those recoveries in the healthcare industry, according to the 12th annual Healthcare Fraud & Abuse Review published today by law firm Bass, Berry & Sims.

Key Points: 
  • In its 12th annual Healthcare Fraud & Abuse Review, Bass, Berry & Sims provides analysis of healthcare fraud enforcement actions and False Claims Act developments probing SCOTUS cases, opioid enforcement and other areas.
  • -- Brian D. Roark
    Qui tam lawsuits filed by whistleblowers under the False Claims Act continue to be a driving force behind the government's civil healthcare fraud enforcement efforts.
  • Other hot-button issues likely will include the intersection of the False Claims Act with cybersecurity issues and the Controlled Substances Act, among others."
  • Providers should expect to see Controlled Substances Act compliance and the False Claims Act continue to intersect in enforcement actions.

Modine Launches New MEW Electric Unit Heaters for Washdown and Corrosive Environments

Retrieved on: 
Mercoledì, Febbraio 28, 2024
HVAC, Ground substance, MEQ, Food, Carbon, Safety, Heat, Agriculture, MEW, MES, Environment

RACINE, Wis., Feb. 28, 2024 /PRNewswire/ -- Modine (NYSE: MOD), a leader in innovative heating solutions in the HVAC industry, has announced the launch of the MEW, a new corrosion-resistant electric unit heater that is designed to be used in non-hazardous washdown and corrosive environments. This new unit provides a heating option for use in the farming and agriculture, food and beverage production, car wash, oil and gas, petrochemical and dairy industries.

Key Points: 
  • The MEW fills the market demand between Modine's full line of commercial electric heaters, HER/VE/PTE, and its top-tier explosion-proof offering, HEX.
  • The MEW is the fifth new electric product Modine has brought to market in the past 12 months.
  • "The Modine® MEW is a new generation of NEMA 4X corrosion-resistant heater for those highly corrosive or washdown areas.
  • The MEW provides NEMA 4X protection against water penetration for longer life in corrosive or washdown environments, and the Epoxy-coated fan blade contributes to longer operational life.

VerifiNow Launches PatientVerifi, A Patient Identity Verification Solution for Telehealth Providers

Retrieved on: 
Lunedì, Febbraio 26, 2024
TEAMS, Telehealth, DEA, National health insurance, Approximation error, Ground substance, Conference, Human, HIPAA, Identity fraud, Health, Patient, Seamless, Privacy, Facial recognition, Drug, Microsoft, Prescription, Zoom, Insurance, Microsoft Teams

PASADENA, Calif., Feb. 26, 2024 /PRNewswire-PRWeb/ -- As the demand for telehealth services surges, VerifiNow announces the launch of PatientVerifi at the ViVE Digital Health Conference in Los Angeles. PatientVerifi is an advanced solution to meet the increasingly crucial need for secure patient identity verification in virtual healthcare.

Key Points: 
  • PatientVerifi is an advanced solution to meet the increasingly crucial need for secure patient identity verification in virtual healthcare.
  • Telehealth's exponential growth necessitates a parallel evolution in patient identity verification.
  • PatientVerifi ensures the patient behind the screen is verified and authenticated with the highest accuracy, preserving the integrity of healthcare services.
  • These requirements are part of the DEA's efforts to maintain patient safety while allowing the convenience of telehealth to support patient care.